Understanding Darzalex Faspro - YouTube
DARZALEX FASPRO-daratumumab
ASH 2021: Combining Daratumumab and Talquetamab - HealthTree for Multiple Myeloma
U.S. Food and Drug Administration Approves DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj), a New Subcutaneous Formulation of Daratumumab in the Treatment of Patients with Multiple Myeloma
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS | Blood Cancer Journal
Subcutaneous Daratumumab for Multiple Myeloma: Applying the Lessons from Clinical Trials to Clinical Practice - Journal of Oncology Navigation & Survivorship
Frontiers | Benefits of switching from intravenous to subcutaneous daratumumab: Perspectives from UK healthcare providers
POMALYST® (pomalidomide) APOLLO Clinical Trial Efficacy & Safety Data
U.S. Food and Drug Administration Approves DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj), a New Subcutaneous Formulation of Daratumumab in the Treatment of Patients with Multiple Myeloma
Frontiers | Benefits of switching from intravenous to subcutaneous daratumumab: Perspectives from UK healthcare providers
Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma | Haematologica
Indications & Dosing | DARZALEX® (daratumumab) & DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) HCP
Darzalex: Uses, Dosage & Side Effects - Drugs.com
Talquetamab-Teclistamab-Daratumumab - Multiple Myeloma Clinical Trials
PRISM- Smoldering Myeloma - Multiple Myeloma Clinical Trials
Indications & Dosing | DARZALEX® (daratumumab) & DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) HCP
Samer Al Hadidi, MD,MS,FACP on X: "#ASH21 #mmsm Oral sessions on trials @ASH_hematology Talquetamab + Daratumumab ➡️around half pts had previous BCMA therapy ➡️F/U only ~4 mo ➡️ ORR of up to
Official Consumer Website | DARZALEX® & DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)
POMALYST® (pomalidomide) APOLLO Clinical Trial Efficacy & Safety Data
Box plot of DARA maximum C trough for nonresponders and responders... | Download Scientific Diagram
U.S. Food and Drug Administration Approves DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj), a New Subcutaneous Formulation of Daratumumab in the Treatment of Patients with Multiple Myeloma
